Clustered Regularly Interspaced Short Palindromic Repeats, known as CRISPR, have become a groundbreaking tool in the field of ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...

On multiple occasions, Kennedy has commented on the potential of CRISPR, a potent and powerful gene-editing tool, to disrupt DNA in unintended and unsafe ways. The nonprofit that RFK Jr.

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, has been hailed as a revolutionary tool in genetic engineering. Formed from an adaptive immune system in bacteria, CRISPR ...

"The FDA's Breakthrough Device Designation for our CRISPR-TB Blood Test is a significant milestone for IntelliGenome. This recognition highlights our commitment to advancing innovative, accessible ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

HOUSTON, Jan. 21, 2025 /PRNewswire/ -- IntelliGenome, an innovative molecular diagnostic solutions provider, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted ...